Evidence map›Paper›PMID 40082315›Full record

ArticleJournal of cardiovascular translational research2025

Human Cardiac Microtissues Display Improved Engraftment and Survival in a Porcine Model of Myocardial Infarction.

Evelyne Demkes, Aina Cervera-Barea, Patricia Ebner-Peking, Martin Wolf, Sarah Hochmann, Amy S Scheren, Mayke Bijsterveld, C Marlies van Oostveen, Marlijn Jansen, Joyce Visser and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiovascular translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Evelyne Demkes *Experimental Cardiology Laboratory, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Aina Cervera-Barea *Experimental Cardiology Laboratory, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. aina.cervera@gmail.com.ORCID 0000-0003-3944-9756
Patricia Ebner-PekingCell Therapy Institute, Paracelsus Medical University, Salzburg, Austria.
Martin WolfCell Therapy Institute, Paracelsus Medical University, Salzburg, Austria.
Sarah HochmannCell Therapy Institute, Paracelsus Medical University, Salzburg, Austria.
Amy S ScherenExperimental Cardiology Laboratory, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Mayke BijsterveldExperimental Cardiology Laboratory, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
C Marlies van OostveenExperimental Cardiology Laboratory, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Marlijn JansenExperimental Cardiology Laboratory, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Joyce VisserExperimental Cardiology Laboratory, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Wiebke TriebertLeibniz Research Laboratories for Biotechnology and Artificial Organs, Hannover Medical School, Hannover, Germany.
Caroline HalloinCell Therapy Process Development, Novo Nordisk A/S, Maaloev, Denmark.
Johannes G G DobbeDepartment of Biomedical Engineering and Physics, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Judith de VosDepartment of Biomedical Engineering and Physics, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Melanie SchürzDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria.
Joachim DanmayrDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria.
Maurice C G AaldersDepartment of Biomedical Engineering and Physics, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Gerard J J BoinkDepartment of Medical Biology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Klaus NeefExperimental Cardiology Laboratory, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Dirk StrunkCell Therapy Institute, Paracelsus Medical University, Salzburg, Austria.
Robert ZweigerdtLeibniz Research Laboratories for Biotechnology and Artificial Organs, Hannover Medical School, Hannover, Germany.
Saskia C A de JagerExperimental Cardiology Laboratory, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Joost P G SluijterExperimental Cardiology Laboratory, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) constitute a promising therapy for myocardial infarction (MI). The lack of an effective immunosuppressive regimen, combined with single-cell transplantations, results in suboptimal outcomes, such as poor engraftment and compromised therapeutic efficacy. This study aimed to confirm the increased retention of hiPSC-CMs microtissues (CMTs) over single-cell grafts. To ensure the long-term survival of CMTs for potential cardiac applications, CMTs were transplanted in a porcine model of MI using a triple immunosuppression protocol designed to limit immune cell infiltration. Acute evaluation of spherical hiPSC-CMs aggregates and dissociated aggregates followed by the development of a triple immunosuppression protocol were performed in healthy animals. Long-term survival of CMTs was later examined in pigs that underwent a transient coronary occlusion. Two weeks post-MI, the immunosuppression treatment was initiated and on day 28 the animals were transplanted with CMTs and followed for four more weeks. Acutely, CMTs showed superior retention compared to their dissociated counterparts. The immunosuppression regimen led to no organ damage and stable levels of circulating drugs once optimal dose was achieved. Two weeks post-xenotransplantation in healthy pigs, histology revealed that immunosuppressed animals displayed a significant decrease in total cellular infiltrates, particularly in CD3

Indexed as

Graft SurvivalInduced Pluripotent Stem CellsMyocardial InfarctionMyocytes, CardiacStem Cell TransplantationAnimalsCells, CulturedCell SurvivalDisease Models, AnimalHumansImmunosuppressive AgentsSus scrofaSwineTime FactorsTransplantation, HeterologousImmunosuppressive AgentsCardiac aggregateCardiac regenerationhiPSC-CMsMyocardial infarctionTranslational researchXenotransplantation

Identifiers

PMID40082315
PMCPMC12208958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.